Table 1

Summary of the most significant results in univariate analysis of the association of ocular and systemic factors with the number of anti-VEGF injections required over 2 years of Observe-and-Plan, an interval-based variable-dosing regimen for neovascular age-related macular degeneration

Factors	n	Mean number of anti-VEGF injections Mean±SD	P values
Overall	205	14.1±5.9
Quartiles	205	10/14/18
Ocular baseline characteristics
RPE detachment baseline
Present ≥200 µm height	57	15.4±0.8	0.054
Absent or <200 µm height	148	13.6±0.5
Per 10 µm thickness increase	205	0.09±0.00 (r=0.27)	0.0001*
CRT baseline
Per 10 µm thickness (corrected for study/SD-OCT machine)	205	0.10±0.003 (r=0.22)	0.002* (0.02*)
Subretinal fluid
Present	18	14.5±0.46	0.17
Absent	46	13.1±0.86
Missing data	1
Per 10 µm thickness increase	204	0.07±0.004 (r=0.12)	0.10
Depigmentation
Present	109	13.3±0.56	0.06
Absent	89	14.9±0.62
Ocular follow-up characteristics
Study
Aflibercept/OCT Spectralis /team 2	100	15.2±0.58	0.01*
Ranibizumab/OCT Cirrus/team 1	105	13.1±0.56
Type of fluid at month 3
Subretinal+intraretinal fluid	25	19.5±1.04
Subretinal fluid only	25	16.9±1.04
Intraretinal fluid only	91	14.1±0.55	<0.0001*
No subretinal or intraretinal fluid	64	11.0±0.65
Subretinal fluid at month 3
Present	50	18.2±0.76	<0.0001*
Absent	155	12.8±0.43
Intraretinal fluid at month 3
Present	116	15.3±0.53
Absent	89	12.6±0.61	0.001*
RPE detachment at month 3
Per 10 µm thickness	205	0.12±0.003 (r=0.27)	<0.0001*
CRT at month 3
Per 10 µm thickness (corrected for study/OCT machine)	205	0.36±0.006 (r=0.38)	<0.0001* (<0.0001*)
Systemic characteristics
BMI (kg/m²)
Per unit	189	−0.13±0.09 (r=−0.11)	0.12
Antidepressant medication
Yes	19	13.8±0.43
No	184	16.0±1.33	0.12
Missing data	2

*P<0.05.
RPE=retinal pigment epithelium; CRT=central retinal thickness; BMI=body mass index.
Anti-VEGF, antivascular endothelial growth factor; BMI, body mass index; CRT, central retinal thickness; RPE, retinal pigment epithelium; SD-OCT, spectral domain optical coherence tomography.